The New York Times analyzes the process whereby Celebrex, an arthritis drug, was promoted by Prizer despite knowing that it was no more effective or safer than other drugs. “Pfizer and its partner. Pharmacia, presented the results from the first six months of a yearlong study rather than the whole thing.” Pfizer defends its decision by saying that 33 million Americans have taken the drug.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.